ALLO
Price
$1.34
Change
-$0.03 (-2.19%)
Updated
Dec 2 closing price
Capitalization
307.88M
91 days until earnings call
Intraday BUY SELL Signals
CABA
Price
$2.34
Change
-$0.09 (-3.70%)
Updated
Dec 2 closing price
Capitalization
233.92M
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs CABA

Header iconALLO vs CABA Comparison
Open Charts ALLO vs CABABanner chart's image
Allogene Therapeutics
Price$1.34
Change-$0.03 (-2.19%)
Volume$2.22M
Capitalization307.88M
Cabaletta Bio
Price$2.34
Change-$0.09 (-3.70%)
Volume$3.06M
Capitalization233.92M
ALLO vs CABA Comparison Chart in %
ALLO
Daily Signal:
Gain/Loss:
CABA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALLO vs. CABA commentary
Dec 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a StrongBuy and CABA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 03, 2025
Stock price -- (ALLO: $1.34 vs. CABA: $2.34)
Brand notoriety: ALLO and CABA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 85% vs. CABA: 64%
Market capitalization -- ALLO: $307.88M vs. CABA: $233.92M
ALLO [@Biotechnology] is valued at $307.88M. CABA’s [@Biotechnology] market capitalization is $233.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileCABA’s FA Score has 1 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • CABA’s FA Score: 1 green, 4 red.
According to our system of comparison, CABA is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while CABA’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 5 bearish.
  • CABA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than CABA.

Price Growth

ALLO (@Biotechnology) experienced а -1.47% price change this week, while CABA (@Biotechnology) price change was +6.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.91%. For the same industry, the average monthly price growth was -4.84%, and the average quarterly price growth was +52.68%.

Reported Earning Dates

ALLO is expected to report earnings on Mar 04, 2026.

CABA is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-1.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($308M) has a higher market cap than CABA($234M). CABA YTD gains are higher at: 3.084 vs. ALLO (-37.089). CABA has higher annual earnings (EBITDA): -140.83M vs. ALLO (-223.22M). ALLO has more cash in the bank: 273M vs. CABA (195M). CABA has less debt than ALLO: CABA (24.9M) vs ALLO (79.2M). ALLO (0) and CABA (0) have equivalent revenues.
ALLOCABAALLO / CABA
Capitalization308M234M132%
EBITDA-223.22M-140.83M159%
Gain YTD-37.0893.084-1,203%
P/E RatioN/AN/A-
Revenue00-
Total Cash273M195M140%
Total Debt79.2M24.9M318%
FUNDAMENTALS RATINGS
ALLO vs CABA: Fundamental Ratings
ALLO
CABA
OUTLOOK RATING
1..100
1973
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
4939
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
83

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (16) in the null industry is significantly better than the same rating for ALLO (96) in the Biotechnology industry. This means that CABA’s stock grew significantly faster than ALLO’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (95) in the Biotechnology industry is in the same range as CABA (96) in the null industry. This means that ALLO’s stock grew similarly to CABA’s over the last 12 months.

CABA's Price Growth Rating (39) in the null industry is in the same range as ALLO (49) in the Biotechnology industry. This means that CABA’s stock grew similarly to ALLO’s over the last 12 months.

CABA's P/E Growth Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOCABA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signal:
Gain/Loss:
CABA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STSBF0.120.02
+15.93%
South Star Battery Metals Corp.
GPAGF20.62N/A
N/A
Gruma S.A.B. de CV
BYLB113.00N/A
N/A
Boyle Bancorp, Inc.
DTSOF6.21N/A
N/A
DTS Corp.
PPRUF337.94-3.08
-0.90%
Kering SA

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-3.70%
SYRE - CABA
44%
Loosely correlated
-0.91%
IPSC - CABA
44%
Loosely correlated
-2.01%
CLDX - CABA
44%
Loosely correlated
+2.89%
BEAM - CABA
43%
Loosely correlated
-2.83%
VYGR - CABA
42%
Loosely correlated
-4.56%
More